As of 2025-07-11, the EV/EBITDA ratio of Castle Biosciences Inc (CSTL) is 17.23. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CSTL's latest enterprise value is 493.45 mil USD. CSTL's TTM EBITDA according to its financial statements is 28.63 mil USD. Dividing these 2 quantities gives us the above CSTL EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 10.4x - 11.4x | 10.8x |
| Forward P/E multiples | 9.7x - 9.7x | 9.7x |
| Fair Price | 12.49 - 14.05 | 12.97 |
| Upside | -37.0% - -29.2% | -34.6% |
| Date | EV/EBITDA |
| 2025-07-10 | 17.23 |
| 2025-07-09 | 17.52 |
| 2025-07-08 | 17.15 |
| 2025-07-07 | 16.85 |
| 2025-07-03 | 17.70 |
| 2025-07-02 | 17.40 |
| 2025-07-01 | 17.74 |
| 2025-06-30 | 17.82 |
| 2025-06-27 | 17.75 |
| 2025-06-26 | 17.14 |
| 2025-06-25 | 16.86 |
| 2025-06-24 | 16.55 |
| 2025-06-23 | 16.23 |
| 2025-06-20 | 15.90 |
| 2025-06-18 | 16.30 |
| 2025-06-17 | 15.92 |
| 2025-06-16 | 16.66 |
| 2025-06-13 | 16.13 |
| 2025-06-12 | 16.20 |
| 2025-06-11 | 15.82 |
| 2025-06-10 | 15.42 |
| 2025-06-09 | 15.55 |
| 2025-06-06 | 14.97 |
| 2025-06-05 | 14.39 |
| 2025-06-04 | 14.39 |
| 2025-06-03 | 14.08 |
| 2025-06-02 | 13.63 |
| 2025-05-30 | 13.33 |
| 2025-05-29 | 13.31 |
| 2025-05-28 | 13.59 |
| 2025-05-27 | 13.16 |
| 2025-05-23 | 13.46 |
| 2025-05-22 | 13.25 |
| 2025-05-21 | 13.38 |
| 2025-05-20 | 13.87 |
| 2025-05-19 | 13.76 |
| 2025-05-16 | 14.12 |
| 2025-05-15 | 13.85 |
| 2025-05-14 | 13.68 |
| 2025-05-13 | 14.40 |
| 2025-05-12 | 14.41 |
| 2025-05-09 | 14.15 |
| 2025-05-08 | 14.58 |
| 2025-05-07 | 14.42 |
| 2025-05-06 | 13.99 |
| 2025-05-05 | 16.13 |
| 2025-05-02 | 16.74 |
| 2025-05-01 | 16.70 |
| 2025-04-30 | 17.44 |
| 2025-04-29 | 17.24 |